Piper Jaffray Cos. reissued their overweight rating on shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) in a research report released on Friday morning. The brokerage currently has a $38.00 price target on the stock.
A number of other brokerages have also issued reports on AIMT. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a research note on Monday, September 12th. Wedbush restated an outperform rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, September 21st. Finally, Credit Suisse Group AG restated a buy rating and issued a $35.00 price target on shares of Aimmune Therapeutics in a research note on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aimmune Therapeutics has a consensus rating of Buy and an average price target of $32.20.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.634% during midday trading on Friday, hitting $16.675. 32,830 shares of the company’s stock were exchanged. The stock’s market cap is $704.59 million. Aimmune Therapeutics has a 1-year low of $9.77 and a 1-year high of $26.50. The stock’s 50 day moving average is $14.76 and its 200-day moving average is $13.65.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. Analysts predict that Aimmune Therapeutics will post ($1.71) earnings per share for the current fiscal year.
In other Aimmune Therapeutics news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the sale, the insider now owns 30,000 shares in the company, valued at $504,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 24.56% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in AIMT. Metropolitan Life Insurance Co. NY raised its stake in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock valued at $130,000 after buying an additional 797 shares during the last quarter. Emerald Acquisition Ltd. purchased a new position in Aimmune Therapeutics during the second quarter valued at approximately $154,000. American International Group Inc. raised its position in Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock valued at $164,000 after buying an additional 8,711 shares in the last quarter. Nationwide Fund Advisors raised its position in Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock valued at $183,000 after buying an additional 9,495 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Aimmune Therapeutics during the second quarter valued at approximately $186,000. Hedge funds and other institutional investors own 68.87% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.